Florence Healthcare

Florence runs a tiered SaaS model. The investigator site portal is free, creating adoption at the point of care. Sponsors and contract research organizations pay for the enterprise tier, which includes remote monitoring tools, compliance dashboards, and site feasibility analytics. The company's Series C with Insight Partners in 2023 funded expansion into the site selection and budget negotiation modules that attach higher per-seat pricing.

The company has publicly named Pfizer, Johnson & Johnson, and several top-20 pharmaceutical firms as enterprise clients. The platform is built for multi-center trials, meaning the same sponsor instance connects to hundreds of investigator sites simultaneously. Florence does not publish a full client list, but the site network's stated scale — over 10,000 connected research sites — implies coverage across the majority of active US trial infrastructure.

No — Florence deliberately avoided the crowded EDC market. The platform manages the regulatory binder, not the case report form data. Investigator site files, delegation logs, and training records live in Florence, while patient outcome data lives in the sponsor's EDC. This adjacency makes Florence complementary to tools like Medidata Rave or Oracle Clinical, and the company integrates with several EDC vendors.

The pandemic accelerated adoption dramatically. Regulators issued emergency guidance allowing remote monitoring of trial sites, and Florence's existing remote source document verification tool saw a surge in deployment. The company states that many sites retained remote monitoring capability even after travel restrictions lifted, permanently reducing the volume of on-site visits sponsors schedule per study.

The company has not filed for an IPO or disclosed specific plans. As of its 2023 Series C, Florence remained privately held with venture backing. The clinical trial software sector has produced recent public listings — Veeva Systems, a larger adjacent player, trades publicly — but Florence has not signaled a timeline for a public offering.